Eletriptan
| Eletriptan | |
|---|---|
| Salts [] | |
|---|---|
| Eletriptan hydrobromide | |
| Eletriptan hemisulfate | |
| Eletriptan succinate | |
| Eletriptan hydrochloride | |
| Eletriptan mesylate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 382.50 g/mol [1] |
| Solubility | Readily soluble as hydrobromide formulation [1] |
| Predicted LogP | 4.1 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C22H26N2O2S |
| IUPAC name | 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole |
| SMILES | CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4 |
| InChI | InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1 |
| InChIKey | PWVXXGRKLHYWKM-LJQANCHMSA-N |
| CAS number | 143322-58-1 |
| UNII | 22QOO9B8KI |
| PubChem CID | 77993 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 4 hours |
| Metabolism | Mainly CYP3A4 |
| Routes of administration | By mouth |
Eletriptan (also known as eletriptanum, Uk 116044, Uk-116044, Uk-116,044, Uk-116044-04 free base, Uk-116,044-04 free base, 5-[2-(benzenesulfonyl)ethyl]-3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-1H-indole, (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole, 3-(((2R)-1-methylpyrrolidin-2-yl)methyl)-5-(2-phenylsulfonylethyl)-1H-indole or 3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-5-(2-phenylsulfonylethyl)-1H-indole) is a substance of the α-alkyltryptamine and tryptamine class.
Chemistry
Salts []
Stereochemistry []
Eletriptan is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Eletriptan matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- analgesics (N02)
- antimigraine preparations (N02C)
- selective serotonin (5ht1) agonists (N02CC)
- (N02CC06)
- eletriptan (N02CC06)
MeSH Classification
- serotonin receptor agonists (M0026371)
Mechanism of action []
Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. In contrast, eletriptan displays insignificant pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. While the full mechanism of action of 5-HT receptor agonists in relieving migrains is not fully elucidated, it is proposed that the activation of 5-HT1 receptors located on intracranial blood vessels leads to vasoconstriction that correlates with the relief of migraine headaches. It is also proposed that the activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system leads to the inhibition of release of pro-inflammatory neuropeptides. [1]
Interactions []
Medical side effects []
238 side effects listed on drug labels in SIDER 4.1 (eletriptan).
- Dizziness
- Syncope
- Somnolence
- Drowsiness
- Asthenia
- Fatigue
- Back pain
- Hypoaesthesia
- Numbness
- Hypertonia
- Nausea
- Palpitations
- Pharyngitis
- Hyperhidrosis
- Vertigo
- Chills
- Headache
- Paraesthesia
- Tingling sensation
- Dry mouth
- Abdominal pain
- Stomach ache
- Gastrointestinal pain
- Dysphagia
- Dyspepsia
- Flushing
- Muscle spasms
- Pain
- Abdominal pain upper
- Chest discomfort
- Discomfort
- Malaise
- Throat tightness
- Feeling hot
- Decreased appetite
- Anxiety
- Arthralgia
- Musculoskeletal discomfort
- Myalgia
- Arthritis
- Rheumatoid arthritis
- Asthma
- Ataxia
- Confusional state
- Feeling abnormal
- Conjunctivitis
- Constipation
- Depersonalisation
- Diarrhoea
- Dysgeusia
- Dyspnoea
- Ear pain
- Oedema
- Eructation
- Oesophagitis
- Dermatitis
- Rash
- Flatulence
- Gastritis
- Gastrointestinal disorder
- Glossitis
- Hyperaesthesia
- Hyperpathia
- Hypertension
- Lacrimal disorder
- Lacrimal structural disorder
- Nervousness
- Tension
- Polyuria
- Urine output increased
- Pruritus
- Respiratory tract infection
- Rhinitis
- Salivary hypersecretion
- Skin disorder
- Unspecified disorder of skin and subcutaneous tissue
- Speech disorder
- Tachycardia
- Thirst
- Tinnitus
- Tremor
- Pollakiuria
- Urethral disorder
- Urinary tract disorder
- Yawning
- Peripheral vascular disorder
- Stupor
- Depressed level of consciousness
- Agitation
- Hyperkinesia
- Apathy
- Flat affect
- Mood swings
- Affect lability
- Photophobia
- Oedema peripheral
- Migraine
- Blood creatine phosphokinase increased
- Liver function test abnormal
- Bone pain
- Eye pain
- Ill-defined disorder
- Thinking abnormal
- Mental disability
- Abnormal dreams
- Euphoric mood
- Erectile dysfunction
- Coordination abnormal
- Face oedema
- Insomnia
- Muscular weakness
- Visual impairment
- Abscess
- Alopecia
- Amnesia
- Anaemia
- Angina pectoris
- Aphasia
- Arrhythmia
- Atrial fibrillation
- Atrioventricular block
- Bone neoplasm
- Bronchitis
- Candida infection
- Cerebrovascular disorder
- Cyanosis
- Dermatitis exfoliative
- Diplopia
- Ear disorder
- Eczema
- Epistaxis
- Eye haemorrhage
- Body temperature increased
- Gingivitis
- Goitre
- Breath odour
- Hallucination
- Haematemesis
- Hemiplegia
- Hernia
- Hiccups
- Hyperbilirubinaemia
- Hyperglycaemia
- Hypersensitivity
- Hyperventilation
- Hypotension
- Body temperature decreased
- Hypothermia
- Conversion disorder
- Influenza
- Arthropathy
- Osteoarthritis
- Laryngitis
- Leukopenia
- Vaginal discharge
- Breast pain
- Menorrhagia
- Menstrual disorder
- Myopathy
- Neurosis
- Otitis media
- Psoriasis
- Purpura
- Vascular purpura
- Anorectal disorder
- Convulsion
- Shock
- Sinusitis
- Stomatitis
- Loss of consciousness
- Tenosynovitis
- Thrombophlebitis
- Thyroiditis
- Tongue disorder
- Tongue oedema
- Tooth disorder
- Urticaria
- Vaginal inflammation
- Vaginal infection
- Vomiting
- Weight increased
- Weight decreased
- Ventricular arrhythmia
- Vasospasm
- Oculogyric crisis
- Monocytosis
- Hypokinesia
- Thyroid adenoma
- Skin hypertrophy
- Injury
- Mania
- Blood alkaline phosphatase increased
- Skin discolouration
- Dry skin
- Accommodation disorder
- Muscle twitching
- Increased appetite
- Sputum increased
- Increased bronchial secretion
- Major depression
- Dry eye
- Abdominal distension
- Rash maculo-papular
- Bradycardia
- Laboratory test abnormal
- Neuropathy peripheral
- Lymphadenopathy
- Dementia
- Paralysis
- Choking sensation
- Renal pain
- Cough
- Gait disturbance
- Sleep disorder
- Parosmia
- Catatonia
- Prinzmetal angina
- Angioedema
- Arteriospasm coronary
- Hypertensive crisis
- Immune system disorder
- Muscle atrophy
- Myocardial infarction
- Acute coronary syndrome
- Nervous system disorder
- Sensory loss
- Ventricular fibrillation
- Ventricular tachycardia
- Viral infection
- Burning sensation
- Myocardial ischaemia
- Colitis ischaemic
- Abdominal discomfort
- Gastrointestinal discomfort
- Pain in jaw
- Blood pressure increased
- Serotonin syndrome
- Medication overuse headache
Indications
- Aura
- Basilar migraine
- Cluster headache
- Hypertension
- Migraine
- Uncontrolled hypertension
Legal status []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 77993, Eletriptan. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/77993
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Eletriptan. UNII: 22QOO9B8KI. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/22QOO9B8KI
Relpax 20mg Film-Coated Tablets. - Summary of Product Characteristics (SmPC). (emc). 3 July 2020. https://www.medicines.org.uk/emc/product/1568/smpc
Relpax- eletriptan hydrobromide tablet, film coated. DailyMed. 10 December 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=986dc112-b97b-44a3-bfaf-074f906f8bb2
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 09:10:00 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 09:09:56 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 09:09:56 |
| gsrs | ok | 2026-11-20 09:10:00 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014361) | 2026-11-20 09:09:56 |
| kegg | ok | 2026-11-20 09:09:58 |
| pubchem | ok | 2026-11-20 09:09:56 |
| missing (no r/tripreports posts mention it) | 2026-11-20 09:09:56 | |
| sider | ok | 2026-11-20 09:09:56 |
| structure | ok | 2026-11-20 09:09:56 |
| wikipedia | ok | 2026-11-20 09:09:57 |